← Back to Screener
Zenas BioPharma, Inc. Common Stock (ZBIO)
Price$17.47
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-62.93%
Price vs S&P 500 (4W)-11.04%
VGM Score66.32
Market Capitalization$1.10B
All Metrics
Book Value / Share (Quarterly)$5.38
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.94
Price vs S&P 500 (YTD)-60.04%
EPS (TTM)$-8.45
10-Day Avg Trading Volume0.52M
EPS Excl Extra (TTM)$-8.45
EPS (Annual)$-8.44
ROI (Annual)-117.76%
Cash / Share (Quarterly)$11.50
ROA (Last FY)-98.46%
Revenue Growth TTM (YoY)100.00%
EBITD / Share (TTM)$-8.78
Cash Flow / Share (Annual)$-3.81
P/B Ratio3.27x
P/B Ratio (Quarterly)3.46x
Net Income / Employee (Annual)$-2,261,900
ROA (TTM)-97.38%
EPS Incl Extra (Annual)$-8.44
Current Ratio (Annual)5.61x
Quick Ratio (Quarterly)11.73x
3-Month Avg Trading Volume0.70M
52-Week Price Return81.79%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)109.85x
Asset Turnover (Annual)0.03x
52-Week High$44.60
EPS Excl Extra (Annual)$-8.44
26-Week Price Return-55.01%
Quick Ratio (Annual)5.48x
13-Week Price Return-30.84%
Total Debt / Equity (Annual)0.32x
Current Ratio (Quarterly)11.94x
Enterprise Value$948.91M
Revenue / Employee (Annual)$59,900
Pretax Margin (Annual)-3778.16%
Cash / Share (Annual)$6.30
3-Month Return Std Dev77.27%
Net Income / Employee (TTM)$-2,545,800
ROE (Last FY)-156.00%
EPS Basic Excl Extra (Annual)$-8.44
Total Debt / Equity (Quarterly)1.04x
EPS Incl Extra (TTM)$-8.45
ROI (TTM)-112.16%
Revenue / Share (Annual)$0.22
Price vs S&P 500 (52W)57.42%
Year-to-Date Return-51.89%
5-Day Price Return-3.85%
EPS Normalized (Annual)$-8.44
Net Profit Margin (Annual)-3777.37%
Month-to-Date Return-5.05%
EBITD / Share (Annual)$-8.56
Operating Margin (Annual)-3830.57%
LT Debt / Equity (Annual)0.32x
LT Debt / Equity (Quarterly)1.04x
EPS Basic Excl Extra (TTM)$-8.45
P/B Ratio (Annual)8.05x
Book Value / Share (Annual)$4.44
Price vs S&P 500 (13W)-39.09%
Beta0.70x
Revenue / Share (TTM)$0.00
ROE (TTM)-167.71%
52-Week Low$8.91
gGradeA
mGradeC
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-1.46est. -1.62
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.36
4.36
4.36
4.36
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZBIOZenas BioPharma, Inc. Common Stock | — | A | C | $17.47 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on treating autoimmune diseases with obexelimab, a monoclonal antibody. The drug candidate targets B cells by binding to CD19 and FcyRIIb receptors, inhibiting their disease-driving activity while preserving cell survival—a mechanism designed to provide a differentiated treatment approach. This unique profile addresses a significant gap in autoimmune disease therapy.